JP4301571B2 - 改良された生物学的利用能を有する医薬のプロドラッグ - Google Patents

改良された生物学的利用能を有する医薬のプロドラッグ Download PDF

Info

Publication number: JP4301571B2
Authority: JP; Japan
Prior art keywords: group; compound; alkyl; acyl; general formula
Prior art date: 1995-06-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP50218097A

Other languages

English (en)

Japanese (ja)

Other versions

JPH11512078A5 (2

JPH11512078A (ja

Inventor

ワイ．ホステトラー、カール

ディー．キニ、ガネシュ

アール．ビードル、ジェイムズ

Original Assignee

カールワイ．ホステトラー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-07

Publication date

2009-07-22

1996-06-07 Application filed by カールワイ．ホステトラー filed Critical カールワイ．ホステトラー

1999-10-19 Publication of JPH11512078A publication Critical patent/JPH11512078A/ja

2004-07-29 Publication of JPH11512078A5 publication Critical patent/JPH11512078A5/ja

2009-07-22 Application granted granted Critical

2009-07-22 Publication of JP4301571B2 publication Critical patent/JP4301571B2/ja

2016-06-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

229940002612 prodrug Drugs 0.000 title abstract description 52
239000000651 prodrug Substances 0.000 title abstract description 52
239000000203 mixture Substances 0.000 claims abstract description 98
239000003814 drug Substances 0.000 claims abstract description 90
229940079593 drug Drugs 0.000 claims abstract description 81
150000002632 lipids Chemical class 0.000 claims abstract description 69
238000000034 method Methods 0.000 claims abstract description 44
230000000840 anti-viral effect Effects 0.000 claims abstract description 37
150000001875 compounds Chemical class 0.000 claims description 152
-1 1-O-hexadecylpropanediol-3-phospho-dideoxyadenosine Chemical compound 0.000 claims description 47
239000002502 liposome Substances 0.000 claims description 34
229910019142 PO4 Inorganic materials 0.000 claims description 28
239000010452 phosphate Substances 0.000 claims description 28
238000005859 coupling reaction Methods 0.000 claims description 22
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
229960004150 aciclovir Drugs 0.000 claims description 21
230000008878 coupling Effects 0.000 claims description 21
238000010168 coupling process Methods 0.000 claims description 21
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 21
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
108090000765 processed proteins & peptides Proteins 0.000 claims description 19
125000000217 alkyl group Chemical group 0.000 claims description 18
125000003277 amino group Chemical group 0.000 claims description 18
239000002777 nucleoside Substances 0.000 claims description 18
238000009472 formulation Methods 0.000 claims description 17
239000003443 antiviral agent Substances 0.000 claims description 15
239000003795 chemical substances by application Substances 0.000 claims description 15
125000005647 linker group Chemical group 0.000 claims description 14
238000001990 intravenous administration Methods 0.000 claims description 13
150000003833 nucleoside derivatives Chemical class 0.000 claims description 12
150000003904 phospholipids Chemical group 0.000 claims description 12
230000003612 virological effect Effects 0.000 claims description 12
125000002252 acyl group Chemical group 0.000 claims description 10
229920006395 saturated elastomer Polymers 0.000 claims description 10
125000000524 functional group Chemical group 0.000 claims description 9
238000007918 intramuscular administration Methods 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
238000007920 subcutaneous administration Methods 0.000 claims description 9
230000001225 therapeutic effect Effects 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
208000036142 Viral infection Diseases 0.000 claims description 7
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 7
239000003242 anti bacterial agent Substances 0.000 claims description 6
241000894007 species Species 0.000 claims description 6
229960002963 ganciclovir Drugs 0.000 claims description 5
229910052740 iodine Inorganic materials 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
229910052794 bromium Inorganic materials 0.000 claims description 4
150000001768 cations Chemical class 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
238000011200 topical administration Methods 0.000 claims description 4
125000005270 trialkylamine group Chemical group 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 3
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 3
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
230000001177 retroviral effect Effects 0.000 claims description 2
238000006467 substitution reaction Methods 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
KGLYUHXSJFMUDI-UHFFFAOYSA-N 1,3-dioxolane;7h-purine-2,8-diamine Chemical compound C1COCO1.NC1=NC=C2NC(N)=NC2=N1 KGLYUHXSJFMUDI-UHFFFAOYSA-N 0.000 claims 1
XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 claims 1
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims 1
OCLZPNCLRLDXJC-UHFFFAOYSA-N 2-amino-9-[5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C1CCC(CO)O1 OCLZPNCLRLDXJC-UHFFFAOYSA-N 0.000 claims 1
208000035143 Bacterial infection Diseases 0.000 claims 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 1
JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims 1
235000014676 Phragmites communis Nutrition 0.000 claims 1
206010038997 Retroviral infections Diseases 0.000 claims 1
125000000539 amino acid group Chemical group 0.000 claims 1
230000000844 anti-bacterial effect Effects 0.000 claims 1
208000022362 bacterial infectious disease Diseases 0.000 claims 1
201000010099 disease Diseases 0.000 abstract description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
230000001093 anti-cancer Effects 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
239000008177 pharmaceutical agent Substances 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 83
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 67
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 62
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 52
239000000243 solution Substances 0.000 description 47
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 42
238000003786 synthesis reaction Methods 0.000 description 41
230000015572 biosynthetic process Effects 0.000 description 39
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
238000006243 chemical reaction Methods 0.000 description 29
239000000047 product Substances 0.000 description 29
239000002904 solvent Substances 0.000 description 27
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
230000000694 effects Effects 0.000 description 25
210000001519 tissue Anatomy 0.000 description 25
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 23
210000004027 cell Anatomy 0.000 description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
239000011541 reaction mixture Substances 0.000 description 21
239000007787 solid Substances 0.000 description 21
238000003818 flash chromatography Methods 0.000 description 18
ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 18
238000002360 preparation method Methods 0.000 description 18
239000000741 silica gel Substances 0.000 description 17
229910002027 silica gel Inorganic materials 0.000 description 17
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
HRBGUGQWTMBDTR-UHFFFAOYSA-N 2,3,4-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC=C(S(Cl)(=O)=O)C(C(C)C)=C1C(C)C HRBGUGQWTMBDTR-UHFFFAOYSA-N 0.000 description 15
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
230000002829 reductive effect Effects 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
239000002253 acid Substances 0.000 description 14
241000701024 Human betaherpesvirus 5 Species 0.000 description 13
241000700584 Simplexvirus Species 0.000 description 13
238000010521 absorption reaction Methods 0.000 description 13
229910052757 nitrogen Inorganic materials 0.000 description 13
239000012043 crude product Substances 0.000 description 12
XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 11
241000700605 Viruses Species 0.000 description 11
241000725303 Human immunodeficiency virus Species 0.000 description 10
239000000706 filtrate Substances 0.000 description 10
ZNVBMQIWZIDDCS-UHFFFAOYSA-N 3-octadecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOCCCO ZNVBMQIWZIDDCS-UHFFFAOYSA-N 0.000 description 9
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical group CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 9
238000004587 chromatography analysis Methods 0.000 description 9
150000004712 monophosphates Chemical class 0.000 description 9
238000003756 stirring Methods 0.000 description 9
YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 8
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 8
JAPYIBBSTJFDAK-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 JAPYIBBSTJFDAK-UHFFFAOYSA-N 0.000 description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 7
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
230000008901 benefit Effects 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
238000007912 intraperitoneal administration Methods 0.000 description 7
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical group CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 6
241000700588 Human alphaherpesvirus 1 Species 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
239000003480 eluent Substances 0.000 description 6
125000004494 ethyl ester group Chemical class 0.000 description 6
239000000796 flavoring agent Substances 0.000 description 6
150000004702 methyl esters Chemical class 0.000 description 6
239000003921 oil Substances 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000003755 preservative agent Substances 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
125000003396 thiol group Chemical group [H]S* 0.000 description 6
230000009385 viral infection Effects 0.000 description 6
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 5
ZPSAJIRHIOBQIT-UHFFFAOYSA-N 3-octadecoxypropyl dihydrogen phosphate Chemical group CCCCCCCCCCCCCCCCCCOCCCOP(O)(O)=O ZPSAJIRHIOBQIT-UHFFFAOYSA-N 0.000 description 5
241000701022 Cytomegalovirus Species 0.000 description 5
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 5
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 5
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
241000714223 Rauscher murine leukemia virus Species 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
229960005102 foscarnet Drugs 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
KNPLQZXBTKKRAJ-UHFFFAOYSA-N octadecyl methanesulfonate Chemical compound CCCCCCCCCCCCCCCCCCOS(C)(=O)=O KNPLQZXBTKKRAJ-UHFFFAOYSA-N 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
238000000746 purification Methods 0.000 description 5
210000000813 small intestine Anatomy 0.000 description 5
239000007858 starting material Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
JWBOVDKFGDXGCR-QFIPXVFZSA-N (2s)-2-methoxy-3-octadecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOC[C@H](CO)OC JWBOVDKFGDXGCR-QFIPXVFZSA-N 0.000 description 4
AVIFKOIVNVRTPE-NDEPHWFRSA-N (2s)-3-octadecoxy-2-phenylmethoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOC[C@H](CO)OCC1=CC=CC=C1 AVIFKOIVNVRTPE-NDEPHWFRSA-N 0.000 description 4
QXPSQIATWDRYBF-UHFFFAOYSA-N 2,2-dimethoxy-3-octadecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(CO)(OC)OC QXPSQIATWDRYBF-UHFFFAOYSA-N 0.000 description 4
KUOAJOVOKFATQE-UHFFFAOYSA-N 2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethyl dihydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOP(O)(O)=O)C=N2 KUOAJOVOKFATQE-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
241000282412 Homo Species 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
229930012538 Paclitaxel Natural products 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
238000013459 approach Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000007900 aqueous suspension Substances 0.000 description 4
IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 4
229960001139 cefazolin Drugs 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000010549 co-Evaporation Methods 0.000 description 4
239000003086 colorant Substances 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
229940000406 drug candidate Drugs 0.000 description 4
WBIAZONFXLIADH-UHFFFAOYSA-N ethoxycarbonylphosphonic acid Chemical compound CCOC(=O)P(O)(O)=O WBIAZONFXLIADH-UHFFFAOYSA-N 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
239000006260 foam Substances 0.000 description 4
230000037406 food intake Effects 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
239000010410 layer Substances 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
125000003835 nucleoside group Chemical group 0.000 description 4
239000002674 ointment Substances 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
229960001592 paclitaxel Drugs 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000003239 susceptibility assay Methods 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
239000003765 sweetening agent Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
229940122440 HIV protease inhibitor Drugs 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
206010041660 Splenomegaly Diseases 0.000 description 3
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
235000013405 beer Nutrition 0.000 description 3
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
239000002775 capsule Substances 0.000 description 3
ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 3
229960000484 ceftazidime Drugs 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
239000007822 coupling agent Substances 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000003651 drinking water Substances 0.000 description 3
235000020188 drinking water Nutrition 0.000 description 3
150000002191 fatty alcohols Chemical class 0.000 description 3
235000019634 flavors Nutrition 0.000 description 3
235000003599 food sweetener Nutrition 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
239000004030 hiv protease inhibitor Substances 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
239000011630 iodine Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229940127073 nucleoside analogue Drugs 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000002688 persistence Effects 0.000 description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 3
238000002962 plaque-reduction assay Methods 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
238000010791 quenching Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000011669 selenium Substances 0.000 description 3
238000010898 silica gel chromatography Methods 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
150000007970 thio esters Chemical class 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
SWSFIBLZYBMINH-UHFFFAOYSA-N (2,2-dimethoxy-3-octadecoxypropoxy)carbonylphosphonic acid Chemical compound P(=O)(O)(O)C(=O)OCC(COCCCCCCCCCCCCCCCCCC)(OC)OC SWSFIBLZYBMINH-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
CIKLYZZADNWVMV-UHFFFAOYSA-N 1-hydroxypropyl dihydrogen phosphate Chemical compound CCC(O)OP(O)(O)=O CIKLYZZADNWVMV-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
JGNKEQZDRNPPNL-UHFFFAOYSA-N 2,2-dimethoxypropane-1,1-diol Chemical compound COC(C)(OC)C(O)O JGNKEQZDRNPPNL-UHFFFAOYSA-N 0.000 description 2
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 2
GHSBJDZSBNDAGL-UHFFFAOYSA-N 2-(tritylamino)ethanol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(NCCO)C1=CC=CC=C1 GHSBJDZSBNDAGL-UHFFFAOYSA-N 0.000 description 2
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
QSZUQLUMBUSQNJ-XMMPIXPASA-N 2-aminoethyl [(2r)-2-methoxy-3-octadecoxypropyl] hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP(O)(=O)OCCN QSZUQLUMBUSQNJ-XMMPIXPASA-N 0.000 description 2
WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 2
SHLSSLVZXJBVHE-UHFFFAOYSA-N 3-sulfanylpropan-1-ol Chemical compound OCCCS SHLSSLVZXJBVHE-UHFFFAOYSA-N 0.000 description 2
FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 2
OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 2
NKGPJODWTZCHGF-UHFFFAOYSA-N 9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound OC1C(O)C(CO)OC1N1C(NC=NC2=S)=C2N=C1 NKGPJODWTZCHGF-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
FEYSUFXTFUKUAV-QQCYDSABSA-N C([C@@H](COCCCCCCCCCCCCCCCCCC)OCC=1C=CC=CC=1)OP(O)(=O)C(C(O)=O)C(C=1C=CC=CC=1)NC(=O)C1=CC=CC=C1 Chemical compound C([C@@H](COCCCCCCCCCCCCCCCCCC)OCC=1C=CC=CC=1)OP(O)(=O)C(C(O)=O)C(C=1C=CC=CC=1)NC(=O)C1=CC=CC=C1 FEYSUFXTFUKUAV-QQCYDSABSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
229940126657 Compound 17 Drugs 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
102000011720 Lysophospholipase Human genes 0.000 description 2
108020002496 Lysophospholipase Proteins 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
LSJIZCGOXSEZNF-UHFFFAOYSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]-3-hydroxypropyl] dihydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COP(O)(O)=O)C=N2 LSJIZCGOXSEZNF-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
150000001414 amino alcohols Chemical class 0.000 description 2
230000003622 anti-hsv Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
LVKZSFMYNWRPJX-UHFFFAOYSA-N benzenearsonic acid Natural products O[As](O)(=O)C1=CC=CC=C1 LVKZSFMYNWRPJX-UHFFFAOYSA-N 0.000 description 2
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
229960004755 ceftriaxone Drugs 0.000 description 2
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
238000006264 debenzylation reaction Methods 0.000 description 2
OSIAURSWRZARKZ-UHFFFAOYSA-N dihydroxyphosphinothioylformic acid Chemical compound OC(=O)P(O)(O)=S OSIAURSWRZARKZ-UHFFFAOYSA-N 0.000 description 2
239000003118 drug derivative Substances 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
MPTKFBJYKPUIGE-YZRHJBSPSA-N ethyl dichlorophosphorylformate Chemical compound C(C)O[14C](=O)P(=O)(Cl)Cl MPTKFBJYKPUIGE-YZRHJBSPSA-N 0.000 description 2
230000003631 expected effect Effects 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000003205 fragrance Substances 0.000 description 2
238000003304 gavage Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
230000036541 health Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000006166 lysate Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
CYQYCASVINMDFD-UHFFFAOYSA-N n,n-ditert-butyl-2-methylpropan-2-amine Chemical class CC(C)(C)N(C(C)(C)C)C(C)(C)C CYQYCASVINMDFD-UHFFFAOYSA-N 0.000 description 2
229940042880 natural phospholipid Drugs 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
230000035515 penetration Effects 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
239000006187 pill Substances 0.000 description 2
229960002292 piperacillin Drugs 0.000 description 2
WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 2
238000012746 preparative thin layer chromatography Methods 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
239000001294 propane Substances 0.000 description 2
239000012264 purified product Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
235000010384 tocopherol Nutrition 0.000 description 2
229960001295 tocopherol Drugs 0.000 description 2
229930003799 tocopherol Natural products 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
OAGWAXJCPQEGJG-UHFFFAOYSA-N (2,2-dimethoxy-3-octadecoxypropyl) dihydroxyphosphinothioylformate Chemical compound P(=S)(O)(O)C(=O)OCC(COCCCCCCCCCCCCCCCCCC)(OC)OC OAGWAXJCPQEGJG-UHFFFAOYSA-N 0.000 description 1
FSJPQPQXDUGPFV-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)phosphonic acid Chemical compound CCOC(=O)CP(O)(O)=O FSJPQPQXDUGPFV-UHFFFAOYSA-N 0.000 description 1
LEJMRERYYBRTQY-WDEREUQCSA-N (2r,3r)-2,3-dihydroxy-4-phenylmethoxybutanal Chemical compound O=C[C@H](O)[C@H](O)COCC1=CC=CC=C1 LEJMRERYYBRTQY-WDEREUQCSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
YQYGGOPUTPQHAY-KIQLFZLRSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[2-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(4S,7R)-7-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-carboxy-2-hydrazinylbutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-2-methyl-5,6-dioxooctan-4-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]hydrazinyl]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-hydroxy-3-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1ccccc1)NC(=O)C(CCCCNN[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)[C@H](C)O)C(C)C)[C@H](C)O YQYGGOPUTPQHAY-KIQLFZLRSA-N 0.000 description 1
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
OGBUMNBNEWYMNJ-NRFANRHFSA-N 1-O-octadecyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](O)CO OGBUMNBNEWYMNJ-NRFANRHFSA-N 0.000 description 1
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
HXTCSYUQJHCNFK-UHFFFAOYSA-N 1-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOC(C)O HXTCSYUQJHCNFK-UHFFFAOYSA-N 0.000 description 1
ZWNABPXJDWYWAM-UHFFFAOYSA-N 1-octadecoxypropan-1-ol Chemical group CCCCCCCCCCCCCCCCCCOC(O)CC ZWNABPXJDWYWAM-UHFFFAOYSA-N 0.000 description 1
NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical compound NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 description 1
HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
KUUMDZYFBMADNM-UHFFFAOYSA-N 2-dihydroxyphosphinothioylacetic acid Chemical compound OC(=O)CP(O)(O)=S KUUMDZYFBMADNM-UHFFFAOYSA-N 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
UVNNJJJUOJRHAV-UHFFFAOYSA-N 2-octadecoxyethoxycarbonylphosphonic acid Chemical compound CCCCCCCCCCCCCCCCCCOCCOC(=O)P(O)(O)=O UVNNJJJUOJRHAV-UHFFFAOYSA-N 0.000 description 1
JOIFGFCERYSPEC-UHFFFAOYSA-N 2-octadecoxyethyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(O)(O)=O JOIFGFCERYSPEC-UHFFFAOYSA-N 0.000 description 1
RZARFIRJROUVLM-UHFFFAOYSA-N 3-azaniumyl-2-hydroxy-3-phenylpropanoate Chemical class OC(=O)C(O)C(N)C1=CC=CC=C1 RZARFIRJROUVLM-UHFFFAOYSA-N 0.000 description 1
AVIFKOIVNVRTPE-UHFFFAOYSA-N 3-octadecoxy-2-phenylmethoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(CO)OCC1=CC=CC=C1 AVIFKOIVNVRTPE-UHFFFAOYSA-N 0.000 description 1
RMOJQFVCJSNMES-UHFFFAOYSA-N 3-octadecoxypropoxycarbonylphosphonic acid Chemical compound CCCCCCCCCCCCCCCCCCOCCCOC(=O)P(O)(O)=O RMOJQFVCJSNMES-UHFFFAOYSA-N 0.000 description 1
YCTXPSAULMVEOX-UHFFFAOYSA-N 3-trityloxypropan-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCCO)C1=CC=CC=C1 YCTXPSAULMVEOX-UHFFFAOYSA-N 0.000 description 1
JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 description 1
XQSPYNMVSIKCOC-RITPCOANSA-N 4-amino-5-fluoro-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)SC1 XQSPYNMVSIKCOC-RITPCOANSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
GBEPMLYZCPHOBB-UHFFFAOYSA-N 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound OC(=O)C1=CCSC2CCN12 GBEPMLYZCPHOBB-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
BIASYNXEDDJVGA-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOCCCOC(=O)P(=O)(O)OCC Chemical compound CCCCCCCCCCCCCCCCCCOCCCOC(=O)P(=O)(O)OCC BIASYNXEDDJVGA-UHFFFAOYSA-N 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KQXVERRYBYGQJZ-WRPDIKACSA-N Enalkiren Chemical compound C1=CC(OC)=CC=C1C[C@H](NC(=O)CC(C)(C)N)C(=O)N[C@H](C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)CC(C)C)CC1=CN=CN1 KQXVERRYBYGQJZ-WRPDIKACSA-N 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
GJAARPKBDFKHFS-UHFFFAOYSA-N Gerin Natural products COC(=O)C(=C)C1CC2C(=C)C(=O)C=CC2(C)CC1OC(=O)C GJAARPKBDFKHFS-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000701027 Human herpesvirus 6 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
BVIMEFRTGPIBQR-UHFFFAOYSA-N OC(=O)C(P(O)(O)=O)(P(O)(O)=O)P(O)(O)=O Chemical compound OC(=O)C(P(O)(O)=O)(P(O)(O)=O)P(O)(O)=O BVIMEFRTGPIBQR-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
OIFWQOKDSPDILA-XLPZGREQSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 OIFWQOKDSPDILA-XLPZGREQSA-N 0.000 description 1
RNVYQYLELCKWAN-RXMQYKEDSA-N [(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@@H](CO)O1 RNVYQYLELCKWAN-RXMQYKEDSA-N 0.000 description 1
RLMJCZOXSQPDII-UHFFFAOYSA-N [2-(2,2-dimethoxy-3-octadecoxypropoxy)-2-oxoethyl]-ethoxyphosphinic acid Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)(OC)COC(=O)CP(O)(=O)OCC RLMJCZOXSQPDII-UHFFFAOYSA-N 0.000 description 1
BKWIXPAEQDWSDE-UHFFFAOYSA-N [ethoxy(hydroxy)phosphoryl]formic acid Chemical compound CCOP(O)(=O)C(O)=O BKWIXPAEQDWSDE-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001263 acyl chlorides Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
150000001299 aldehydes Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000005257 alkyl acyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940124522 antiretrovirals Drugs 0.000 description 1
239000003903 antiretrovirus agent Substances 0.000 description 1
OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229930014667 baccatin III Natural products 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
229930183167 cerebroside Natural products 0.000 description 1
150000001784 cerebrosides Chemical class 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000020176 deacylation Effects 0.000 description 1
238000005947 deacylation reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
229960004281 desmopressin Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
229950008153 enalkiren Drugs 0.000 description 1
108010049503 enalkiren Proteins 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
150000002169 ethanolamines Chemical class 0.000 description 1
239000004210 ether based solvent Substances 0.000 description 1
LSFRAQJUMZGQPK-UHFFFAOYSA-N ethoxy(1-octadecoxyethoxycarbonyl)phosphinic acid Chemical compound CCOP(=O)(O)C(=O)OC(C)OCCCCCCCCCCCCCCCCCC LSFRAQJUMZGQPK-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
238000010265 fast atom bombardment Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
239000005457 ice water Substances 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000009061 membrane transport Effects 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
XTAZYLNFDRKIHJ-UHFFFAOYSA-N n,n-dioctyloctan-1-amine Chemical compound CCCCCCCCN(CCCCCCCC)CCCCCCCC XTAZYLNFDRKIHJ-UHFFFAOYSA-N 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
108010092541 pentapeptide 7194 Proteins 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
125000001095 phosphatidyl group Chemical group 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920001184 polypeptide Chemical class 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000166 polytrimethylene carbonate Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
OENLEHTYJXMVBG-UHFFFAOYSA-N pyridine;hydrate Chemical compound [OH-].C1=CC=[NH+]C=C1 OENLEHTYJXMVBG-UHFFFAOYSA-N 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
229920006012 semi-aromatic polyamide Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
MOSCXNXKSOHVSQ-UHFFFAOYSA-M sodium;2-hydroxybutanoate Chemical compound [Na+].CCC(O)C([O-])=O MOSCXNXKSOHVSQ-UHFFFAOYSA-M 0.000 description 1
238000000527 sonication Methods 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
229960002135 sulfadimidine Drugs 0.000 description 1
ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000008685 targeting Effects 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
CVYZCIFAHYJSCQ-UHFFFAOYSA-N trifluoro(diphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(F)(F)(F)C1=CC=CC=C1 CVYZCIFAHYJSCQ-UHFFFAOYSA-N 0.000 description 1
IIYTXTQVIDHSSL-UHFFFAOYSA-N trimethylsilylmethanethiol Chemical compound C[Si](C)(C)CS IIYTXTQVIDHSSL-UHFFFAOYSA-N 0.000 description 1
125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000005866 tritylation reaction Methods 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
229960003636 vidarabine Drugs 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/098—Esters of polyphosphoric acids or anhydrides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
- C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Crystallography & Structural Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP50218097A 1995-06-07 1996-06-07 改良された生物学的利用能を有する医薬のプロドラッグ Expired - Fee Related JP4301571B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/487,081		1995-06-07
US08/487,081 US7517858B1 (en)	1995-06-07	1995-06-07	Prodrugs of pharmaceuticals with improved bioavailability
PCT/US1996/010054 WO1996039831A1 (en)	1995-06-07	1996-06-07	Prodrugs of pharmaceuticals with improved bioavailability

Publications (3)

Publication Number	Publication Date
JPH11512078A JPH11512078A (ja)	1999-10-19
JPH11512078A5 JPH11512078A5 (2)	2004-07-29
JP4301571B2 true JP4301571B2 (ja)	2009-07-22

Family

ID=23934330

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP50218097A Expired - Fee Related JP4301571B2 (ja)	1995-06-07	1996-06-07	改良された生物学的利用能を有する医薬のプロドラッグ

Country Status (9)

Country	Link
US (1)	US7517858B1 (2)
EP (1)	EP0837630B1 (2)
JP (1)	JP4301571B2 (2)
AT (1)	ATE382051T1 (2)
AU (1)	AU711774B2 (2)
CA (1)	CA2223989C (2)
DE (1)	DE69637381T2 (2)
ES (1)	ES2299178T3 (2)
WO (1)	WO1996039831A1 (2)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9603726D0 (sv) *	1996-10-11	1996-10-11	Astra Ab	Novel compounds
JP2002502831A (ja) *	1998-02-03	2002-01-29	イネックスファーマシューティカルズコーポレイション	癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
US6410328B1 (en)	1998-02-03	2002-06-25	Protiva Biotherapeutics Inc.	Sensitizing cells to compounds using lipid-mediated gene and compound delivery
IL131887A0 (en) *	1999-09-14	2001-03-19	Dpharm Ltd	Phospholipid prodrugs of anti-proliferative drugs
EP1244459A2 (en) *	1999-12-29	2002-10-02	The Regents of the University of California	Treatment of drug-resistant human immunodeficiency virus infection
EP1460082A1 (en) *	2003-03-19	2004-09-22	Heidelberg Pharma Holding GmbH	Phospholipid esters of clofarabine derivatives
EP1838283B1 (en) *	2004-11-03	2008-12-31	Liplasome Pharma A/S	Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof
CN101094677A (zh)	2004-11-15	2007-12-26	塞普泰尔公司	蛋白酪氨酸磷酸酶抑制剂及其使用方法
WO2006066074A2 (en) *	2004-12-16	2006-06-22	The Regents Of The University Of California	Lung-targeted drugs
AU2007229160A1 (en) *	2006-03-23	2007-09-27	Liplasome Pharma A/S	Lipid based drug delivery systems comprising phospholipase A2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
ES2600792T3 (es) *	2006-05-03	2017-02-10	Chimerix, Inc.	Alcoxialquilésteres metabólicamente estables de fosfonatos, fosfonatos nucleosídicos y fosfatos nucleosídicos antivirales o antiproliferativos
JP5620272B2 (ja) *	2007-11-09	2014-11-05	プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａＢｉｏＰｈａｒｍａＮｏｒｇｅＡＳ	化粧品において，食品サプリメントとして，または医薬品として用いるための脂質化合物
EP2070938A1 (en) *	2007-12-13	2009-06-17	Heidelberg Pharma AG	Clofarabine dietherphospholipid derivatives
JP2011508740A (ja) *	2007-12-27	2011-03-17	エピファニーバイオサイエンシズ，インク．	抗ウイルス化合物
US8586625B2 (en) *	2008-01-16	2013-11-19	Anwar Rayan	Derivatives of taxol and closely related compounds
EP2147910A1 (en) *	2008-07-15	2010-01-27	Pronova BioPharma Norge AS	Novel lipid compounds
SG175401A1 (en)	2009-05-08	2011-12-29	Pronova Biopharma Norge As	Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US8884027B2 (en)	2010-10-22	2014-11-11	University Of Rochester	Melampomagnolide B derivatives as antileukemic and cytotoxic agents
MY170076A (en)	2010-11-05	2019-07-03	Pronova Biopharma Norge As	Methods of treatment using lipid compounds
WO2014132134A1 (en)	2013-02-28	2014-09-04	Pronova Biopharma Norge As	A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
EA201892769A3 (ru)	2013-03-15	2019-08-30	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Сложные диэфиры ациклических нуклеозидфосфонатов
RU2665135C2 (ru)	2014-03-14	2018-08-28	Олтек, Инк.	Композиции селеноорганических соединений и способы их применения
BR112017005111B1 (pt)	2014-09-15	2023-02-14	The Regents Of The University Of California	Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus
CA2968790A1 (en)	2014-11-26	2016-06-02	Vascular Biogenics Ltd.	Oxidized lipids and treatment or prevention of fibrosis
US9771385B2 (en)	2014-11-26	2017-09-26	Vascular Biogenics Ltd.	Oxidized lipids
CA3182565A1 (en)	2015-03-06	2016-09-15	Atea Pharmaceuticals, Inc.	.beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
BR112017023164A2 (en)	2015-04-28	2018-07-24	Pronova Biopharma Norge As	and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
WO2017048252A1 (en)	2015-09-15	2017-03-23	Alltech, Inc.	Compositions of selenoorganic compounds and methods of use thereof
WO2017048956A1 (en)	2015-09-15	2017-03-23	The Regents Of The University Of California	Nucleotide analogs
US10711029B2 (en)	2016-07-14	2020-07-14	Atea Pharmaceuticals, Inc.	Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
DK3512863T3 (da)	2016-09-07	2022-03-07	Atea Pharmaceuticals Inc	2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
HRP20241643T1 (hr)	2017-12-06	2025-02-14	Basf As	Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
JP7610208B2 (ja) *	2019-03-22	2025-01-08	インテグレイテッドナノセラピューティクスインコーポレイテッド	足場部分から調製した脂質結合体
AU2020334152A1 (en)	2019-08-22	2022-03-24	Emory University	Nucleoside prodrugs and uses related thereto
WO2021173713A1 (en)	2020-02-27	2021-09-02	Atea Pharmaceuticals, Inc.	Highly active compounds against covid-19
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
AU2021330835B2 (en)	2020-08-24	2023-12-14	Gilead Sciences, Inc.	Phospholipid compounds and uses thereof
TW202344257A (zh)	2020-10-16	2023-11-16	美商基利科學股份有限公司	磷脂化合物及其用途
IL318465A (en)	2022-07-21	2025-03-01	Antiva Biosciences Inc	Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasia

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7607496L (sv)	1976-07-01	1978-01-02	Astra Laekemedel Ab	Sett for bekempning av virusinfektioner
CA1144937A (en)	1977-12-22	1983-04-19	Dke J.E. Helgstrand	Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
DE3374837D1 (en) *	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
JPS61152694A (ja) *	1984-12-27	1986-07-11	Toyama Chem Co Ltd	新規な５−フルオロ−２′−デオキシウリジン−５′−ホスフエ−ト誘導体およびその塩
US5223263A (en) *	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
US5072032A (en)	1989-06-21	1991-12-10	Mckenna Charles E	Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid
US5194654A (en)	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) *	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) *	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
AU7872491A (en)	1990-05-07	1991-11-27	Vical, Inc.	Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
DE4111105A1 (de) *	1991-04-05	1992-10-08	Max Planck Gesellschaft	Neue erucyl-, brassidyl- und nervonylderivate
DE4226279A1 (de)	1992-08-08	1994-02-10	Boehringer Mannheim Gmbh	Liponucleotide von Seco-Nucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
US5512671A (en)	1993-02-16	1996-04-30	Wake Forest University	Ether lipid-nucleoside covalent conjugates
US5484911A (en) *	1993-04-01	1996-01-16	Health Research, Inc.	Nucleoside 5'-diphosphate conjugates of ether lipids

1995
- 1995-06-07 US US08/487,081 patent/US7517858B1/en not_active Expired - Fee Related
1996
- 1996-06-07 AT AT96919361T patent/ATE382051T1/de not_active IP Right Cessation
- 1996-06-07 CA CA2223989A patent/CA2223989C/en not_active Expired - Lifetime
- 1996-06-07 JP JP50218097A patent/JP4301571B2/ja not_active Expired - Fee Related
- 1996-06-07 EP EP96919361A patent/EP0837630B1/en not_active Expired - Lifetime
- 1996-06-07 WO PCT/US1996/010054 patent/WO1996039831A1/en not_active Ceased
- 1996-06-07 AU AU61717/96A patent/AU711774B2/en not_active Expired
- 1996-06-07 ES ES96919361T patent/ES2299178T3/es not_active Expired - Lifetime
- 1996-06-07 DE DE69637381T patent/DE69637381T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69637381D1 (de)	2008-02-07
ES2299178T3 (es)	2008-05-16
DE69637381T2 (de)	2008-12-11
AU6171796A (en)	1996-12-30
AU711774B2 (en)	1999-10-21
ATE382051T1 (de)	2008-01-15
EP0837630A4 (en)	1998-11-25
CA2223989C (en)	2010-11-23
US7517858B1 (en)	2009-04-14
EP0837630A1 (en)	1998-04-29
JPH11512078A (ja)	1999-10-19
EP0837630B1 (en)	2007-12-26
CA2223989A1 (en)	1996-12-19
WO1996039831A1 (en)	1996-12-19

Legal Events

Date	Code	Title	Description
2007-09-18	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070918
2008-01-17	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071218
2008-02-04	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080204
2008-02-07	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080117
2008-02-25	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080225
2008-03-06	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080215
2008-03-24	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080324
2008-04-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080317
2009-03-17	TRDD	Decision of grant or rejection written
2009-03-31	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090331
2009-04-02	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2009-04-30	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090421
2009-05-01	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20120501 Year of fee payment: 3
2009-05-01	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2012-04-26	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20120501 Year of fee payment: 3
2012-05-08	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130501 Year of fee payment: 4
2013-04-30	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20140501 Year of fee payment: 5
2014-06-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-05-12	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-05-01	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP4301571B2 (ja)	2009-07-22	改良された生物学的利用能を有する医薬のプロドラッグ
US5696277A (en)	1997-12-09	Antiviral prodrugs
US5484809A (en)	1996-01-16	Prodrugs for oral administration containing taxol or substituted taxol covalently bound to a phospholipid
US5744461A (en)	1998-04-28	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
CA2149753C (en)	2005-11-08	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
AU668873B2 (en)	1996-05-23	Antiviral liponucleosides: treatment of hepatitis B
EP0781138B1 (en)	2008-05-21	Lipid analogs for treating viral infections
US6252060B1 (en)	2001-06-26	Antiviral liponucleosides: treatment of hepatitis B
JPH04501255A (ja)	1992-03-05	抗ウィルス性ヌクレオシドの脂質誘導体、リポソームの取込みおよび使用方法
JP2005505499A (ja)	2005-02-24	ウイルス感染症と癌細胞を二重ターゲッティングする組成物及び方法